This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Web of Science (4) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Anderson, G. L. Articles by Prentice, R. L. Search for Related Content PubMed PubMed Citation Articles by Anderson, G. L. Articles by Prentice, R. L. Social Bookmarking                         What's this?

Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials

Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA, garnet{at}whi.org

Charles Kooperberg

Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Nancy Geller

National Heart Lung Blood Institute, Bethesda, MD, USA

Jacques E. Rossouw

National Heart Lung Blood Institute, Bethesda, MD, USA

Mary Pettinger

Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Ross L. Prentice

Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Background The Women's Health Initiative (WHI) randomized trial of estrogen plus progestin (E + P) was terminated early based on an assessment of harms exceeding benefits for disease prevention. The results contravened prevailing wisdom and a large body of literature regarding benefits of menopausal hormone therapy. The results and their interpretation have been the subject of considerable debate.

Purpose/methods To describe the process of developing a trial monitoring plan, the key interim and final data, and to explain the choice of statistical methods used in trial monitoring and reporting.

Results A formalized monitoring plan was developed using statistical methods that acknowledged protocol-defined design and analysis plans, input of monitoring board members especially regarding the role of various study outcomes, and multiple comparisons. Major early departures from design assumptions concerning treatment effects indicated a need for additional flexibility in safety monitoring. When the trials were stopped early, questions arose as to how closely the statistical methods in published reports should correspond to those defined by protocol or used in monitoring. Methods were selected to provide a simple and transparent summary of the primary results, with a cautious interpretation promoted by acknowledgement of multiple testing.

Conclusions Developing a formal trial monitoring plan with a view towards influencing clinical practice is useful for creating consensus among DSMB members regarding the evidence that would justify stopping a trial and the framework to be used to address statistical complexities. Departures from design assumptions typically occur. These reinforce the role of the DSMB in exercising their judgment, and the judicious adaptation of these statistical guidelines in monitoring and reporting trials. In communicating the results in such circumstances, priority should be given to presenting as fair, accurate and transparent a view of the data and findings as current methods and technology allow.

Clinical Trials, Vol. 4, No. 3, 207-217 (2007)
DOI: 10.1177/1740774507079252


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?